Introduction Revstone ®, a polyherbal formulation available in capsule and syrup forms, is designed to treat kidney-related disorders. However, its renoprotective efficacy remains insufficiently validated. In this study, we aimed to evaluate and compare the renoprotective potential of Revstone ® capsule and syrup formylations in Wistar rats. Objective The aim of this study was to assess the acute toxicity profile of Revstone ® capsule and syrup following Organisation for Economic Co-operation and Development (OECD) guidelines and compare their efficacy in reversing renal damage based on biochemical, histological, and functional markers. Methodology Acute oral toxicity testing was conducted according to the OECD 423 guidelines, and rats were observed for 14 days for mortality, behavioural and clinical changes, body weight variations, and gross necropsy findings. For efficacy evaluation, nephrotoxicity was induced by gentamicin (80 mg/kg i.p. for 7 days). Rats were divided into seven groups, namely, the normal control, disease control, Revstone ® syrup (low and high dose), Revstone ® capsule (low and high dose), and standard drug control (valsartan 10 mg/kg). Renal function was assessed from serum creatinine, blood urea nitrogen, and uric acid levels. Oxidative stress markers such as malondialdehyde (MDA), superoxide dismutase (SOD), and catalase (CAT) were measured, and histopathological evaluation of kidney tissue was performed. Data were analysed using one-way ANOVA followed by Tukey’s post hoc test ( p 0.05). Results Gentamicin significantly elevated renal markers ( p 0.001). Revstone ® syrup at high dose markedly reduced creatinine ( p 0.001), while both formulations improved oxidative stress and renal histology. The syrup formulation was more effective, indicating its potential for future clinical application. Conclusion Revstone ® capsule and syrup demonstrated significant renoprotective activities in gentamicin-induced nephrotoxicity in rats.
Dawane et al. (Tue,) studied this question.